NCT07344220
Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate
Enrolling by Invitation
PHASE2Ages 18+InterventionalTreatmentHoag Memorial Hospital PresbyterianInvestigator-initiated
~39 participants
Updated 2026-01-15 on ClinicalTrials.gov
What's tested:DZ-002 - 5 mg/kg, 6 mg/kg, or 7 mg/kg
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Recommended Phase 2 Dose (RP2D)
Measured over Up to 28 days of last patient dosed during the escalation phase
+1 more outcome measured
Conditions
NCT07344220
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Hoag Memorial Hospital Presbyterian
Newport Beach, Californiano site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Carlos Becerra, MD · PRINCIPAL_INVESTIGATOR · Hoag Memorial Hospital Presbyterian
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Recommended Phase 2 Dose (RP2D)Up to 28 days of last patient dosed during the escalation phase
To determine the RP2D
- Incidence of Dose Limiting Toxicities (DLTs)Up to 28 days
Dose limiting toxicities refer to toxicities experienced during the first 28 days of DZ-002 treatment that have been judged to be clinically significant and related to study treatment.